Skip to main content

Table 6 Summary of sensitivity analyses

From: Microwave ablation compared with hepatic resection for the treatment of hepatocellular carcinoma and liver metastases: a systematic review and meta-analysis

  Main analysis [RR (95% CI); P value; studies (N); I2] Fixed effects [RR (95% CI); P value; studies (N); I2] Exclusion of poor quality studies [RR (95% CI); P value; studies (N); I2] Exclusion of studies with imputed data [RR (95% CI); P value; studies (N); I2]
LTR 2.49 (1.19, 5.22); P = 0.016; 8; 84% 1.56 (1.28, 1.90); P < 0.001; 8; 84% 2.01 (1.06, 3.84); P = 0.033; 7; 72% NA
OS (1-year) 1.01 (0.99, 1.03); P = 0.409; 10; 0% 1.00 (0.97, 1.03); P = 0.977; 10; 0% 1.00 (0.97, 1.03); P = 0.992; 9; 0% NA
OS (3-year) 0.94 (0.88, 0.99); P = 0.03; 10; 0% 0.92 (0.86, 0.99); P = 0.016; 10; 0% 0.94 (0.88, 1.00); P = 0.061; 9; 0% NA
OS (5-year) 0.88 (0.80, 0.97); P = 0.01; 9; 0% 0.87 (0.79, 0.96); P = 0.008; 9; 0% 0.88 (0.79, 0.98); P = 0.025; 8; 0% NA
IDL 1.13 (0.80, 1.60); P = 0.474; 5; 75% 1.12 (0.95, 1.33); P = 0.17; 5; 75% 1.14 (0.74, 1.76); P = 0.544; 4; 81% NA
EHM 1.10 (0.71, 1.72); P = 0.659; 2; 0% 1.09 (0.70, 1.69); P = 0.71; 2; 0% Too few studies (< 2) to inform NA
Operative time (min)* − 58.69 (− 89.55, − 27.83); P < 0.001; 3; 94% − 67.99 (− 74.36, − 61.61); P < 0.001; 3; 94% − 44.61 (− 63.74, − 25.49); P < 0.001; 2; 49% − 58.89 (− 100.15, − 17.63); P = 0.005; 2; 97%
IBL (mL)* − 189.09 (− 324.54, − 53.64); P = 0.006; 3; 93% − 119.88 (− 146.57, − 91.19); P < 0.001; 3; 93% − 189.09 (− 324.54, − 53.64); P = 0.006; 3; 93%  229.28 ( 512.69, 54.12); P = 0.113; 2; 97%
LOS (days)* − 6.16 (− 8.25, − 4.07); P < 0.001; 6; 84% − 7.13 (− 7.78, − 6.48); P < 0.001; 6; 84% − 6.14 (− 8.60, − 3.68); P < 0.001; 5; 87% − 6.5 (− 9.52, − 3.48); P < 0.001; 4; 88%
DFS (1-year) 0.95 (0.90, 1.01); P = 0.085; 8; 39% 0.94 (0.89, 0.99); P = 0.016; 8; 39% 0.95 (0.90, 1.01); P = 0.085; 8; 39% NA
DFS (3-year) 0.78 (0.65, 0.94); P = 0.009; 8; 59% 0.76 (0.68, 0.85); P < 0.001; 8; 59% 0.78 (0.65, 0.94); P = 0.009; 8; 59% NA
DFS (5-year) 0.83 (0.58, 1.17); P = 0.284; 8; 71% 0.79 (0.66, 0.95); P = 0.011; 8; 71% 0.83 (0.58, 1.17); P = 0.284; 8; 71% NA
Overall complications 0.31 (0.19, 0.51); P < 0.001; 9; 10% 0.33 (0.21, 0.50); P < 0.001; 9; 10% 0.32 (0.19,0.55); P < 0.001; 8; 19% NA
Major complications 0.24 (0.10, 0.61); P = 0.002; 4; 0% 0.23 (0.09, 0.59); P = 0.002; 4; 0% Too few studies (< 2) to inform NA
Minor complications 0.45 (0.23, 0.90); P = 0.024; 3; 66% 0.43 (0.32, 0.59); P < 0.001; 3; 66% 1.32 (0.04, 39.86); P = 0.872; 2; 83% NA
  1. *The effect measures for operative time, intraoperative blood loss, and LOS are the weighted mean differences.
  2. Italicized values indicate statistical significance. Point estimates and confidence intervals were calculated using a random effects model apart from the sensitivity using a fixed effects model
  3. Abbreviations: CI confidence interval, DFS disease-free survival, EHM extrahepatic metastases, HCC hepatocellular carcinoma, IBL intraoperative blood loss, IDL intrahepatic de novo lesions, LOS, length of stay, LTR local tumor recurrence, MWA microwave ablation, OS overall survival, RR risk ratio